EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSBSLG00000012270
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSBSLG00000016511
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSBSLG00000025292
Gene Symbol: NR3C1
3 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSBSLG00000006223
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSBSLG00000010171
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSBSLG00000021520
Gene Symbol: OPRD1
3 Cross references
178 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSBSLG00000007833
Gene Symbol: OPRK1
2 Cross references
196 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSBSLG00000012650
Gene Symbol: OXTR
3 Cross references
186 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSBSLG00000023679
Gene Symbol: PTH1R
3 Cross references
198 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSBSLG00000002281
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSBSLG00000008274
Gene Symbol: PPARG
3 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSBSLG00000011730
Gene Symbol: LOC114861502
3 Cross references
384 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).